Timothy Pluard, MD, discusses recent data from an age-based subgroup analysis of RIGHT Choice, which compares the efficacy of combination ribociclib/ET versus chemotherapy in the first-line treatment of HR+/HER2- advanced breast cancer.
Related Keywords
Timothy Pluard , Komal Jhaveri , , Hr Her2 Breast Cancer , Real World Data , Cdk4 6 Inhibitors , Aromatase Inhibitors , Palbociclib , Ribociclib , Abemaciclib , Monarch 3 , Polaris Trial , Fulvestrant , Esr1 , Chemotherapy , Right Choice Trial , Serds , Giredestrant , Camizestrant , Serena 6 ,
comparemela.com © 2020. All Rights Reserved.